STADA Arzneimittel AG / Key word(s): Mergers & Acquisitions
22.07.2011 11:29
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, July 22, 2011 - STADA Arzneimittel AG and Grünenthal GmbH, a
globally active research pharmaceuticals company located in Aachen,
Germany, have today signed the contracts on the purchase of a branded
product portfolio including the associated sales structures for numerous
national markets in Central and Eastern Europe as well as in the Middle
East, after both companies had announced exclusive contract negotiations on
this already on May 12, 2011 (see ad hoc release as of May 12, 2011,
published via DGAP).
The purchase price for the branded product portfolio including sales
structures and various pipeline products amounts to a total of approx. EUR
360 million in cash as already announced in May. The products are for the
most part prescription drugs and positioned primarily in the pain area of
indication. The product portfolio to be acquired consists of over 14 own
and licensed brands for Central and Eastern Europe as well as the Middle
East.
The acquisition requires the approval of the responsible anti-trust
authorities, so that the implementation of the transaction, which was
agreed today, and the consolidation of product sales is expected for the
fourth quarter of 2011. Payment of the purchase price will be made at the
time of completion of the acquisition.
STADA will use cash on hand, free cash flow as well as existing free credit
lines to finance the acquisition. In addition, the placement of a further
corporate bond is currently being examined in this context.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / D -
61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications@stada.de
Or visit us in the Internet at www.stada.com.
22.07.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STADA: STADA and Grünenthal sign contracts on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East
| Source: EQS Group AG